Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease

Endocrine Journal

Volumn 58, Issue 8, 2011, Pages 663-674

  Abe, Masanori ^a   Maruyama, Noriaki ^a   Yoshida, Yoshinori ^a   Ito, Midori ^a   Okada, Kazuyoshi ^a   Soma, Masayoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Albuminuria; Chronic kidney disease; Cystatin C; Malondialdehyde modified LDL (MDA LDL); Rosuvastatin

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CREATININE; CYSTATIN C; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; ROSUVASTATIN; TRIACYLGLYCEROL;

AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; PROTEIN BLOOD LEVEL; RENAL PROTECTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CYTOPROTECTION; DIABETIC NEPHROPATHIES; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 80052607180     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K11E-080     Document Type: Article

References (31)

1. Usui H, Shikata K, Matsuda M Okada S, Ogawa D, Yamashita T, Hida K, Satoh M, Wada J, Makino H (2003) HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 18: 265-272.
2. Stoll LL, McCormick ML, Denning GM, Weintraub NL (2004) Antioxidant effects of statins. Drugs Today 40: 975-990.
3. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, Ciccarese M, Cherchi GM, Maioli M (2000) Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30: 980-987.
4. Enomoto S, Sata M, Fukuda D, Nakara K, Nagai R (2009) Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ProEdeficiant mice. Biomed Pharmacother 63: 19-26.
5. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group (2008) Rosuvastatin prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207.
6. Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM (2006) Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 97: 1602-1606.
7. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR (2003) Development and progression of nephropathy in type 2 diabetes: United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225-232.
8. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T (2005) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28: 164-176.
9. Matsuo S, Imai E, Horio M Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992.
10. Friedewald WT, Levy RI, Fredrikson DS (1972) Estimation of the concentration of low density cholesterol in plasma without the use of a centrifuge. Clin Chem 18: 449-502.
11. Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M (1994) Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochem Biophys Acta 1215: 121-125.
12. Tanaka M, Matsuo K, Enomoto M, Mizuno K. (2004) A sol particle homogeneous immunoassay for measuring serum cystatin C. Clin Biochem 37: 27-35.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) JAMA 285: 2486-2497.
14. Betteridge DJ, Gibson JM (2007) Effects of rosuvas tatin on lipids, lipoproteins and apolipoproteins in the dyslipidemia of diabetes. Diabet Med 24: 541-549.
15. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE (2007) Statins, highdensity lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297: 499-508.
16. Steinberg D (1997) Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272: 20963-20966.
17. Bianchi S, Bigazzi R, Caiazza A, Campese VM (2003) A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-570.
18. Shigematsu S, Takahashi N, Hara M, Yoshimura H, Saikawa T (2007) Increased incidence of coronary instent restenosis in type 2 diabetic patients is related to elevated serum malondialdehyde-modified low-density lipoprotein. Circ J 71: 1697-1702.
19. Tanaga K, Bujo H, Inoue M, Mikami K, Kotani K, Takahashi K, Kanno T, Saito Y (2002) Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Atherioscler Thromb Vasc Biol 22: 662-666.
20. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK (2007) Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2: 1131-1139.
21. Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, de Jong PE, de Jongvan den Berg LT (2006) The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 21: 3106-3114.
22. Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, Miccoli R, Del Prato S, Penno G (2007) Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem 53: 480-488.
23. Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, Plebani M (2002) Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 61: 1453-1461.
24. Ix JH, Shlipak MG, Chertow GM, Whooley MA (2007) Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease. Circulation 115: 173-179.
25. De Leeuw PW, Thijs L, Birkenhäger WH, Voyaki SM, Efstratopoulos AD, Fagard RH, Leonetti G, Nachev C, Petrie JC, Rodicio JL, Rosenfeld JJ, Sarti C, Staessen JA; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators (2002) Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 13: 2213-2222.
26. Marin R, Gorostidi M, Fernandez-Vega F, Alvarez- Navascues R (2005) Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis. Kidney Int Suppl 99: S52-56.
27. Viberti G, Wheeldon MN, for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106: 672-678.
28. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I (2001) Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860.
29. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin- converting enzyme inhibition, a patient-level meta-analysis. Ann Intern Med 139: 244-52.
30. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC (2003) Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14: 1605-1613.
31. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H (2005) Effect of pitavastatin on urinary livertype fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 28:2728-2732.